Tissue Model
Conditions
Brief summary
The HERO project aims to structure an ex vivo screening platform, based on anonymized human tissues, to early assess the tissue fixation of experimental ligands in an ethical, translational approach that complies with the principles of the 3Rs (Replacement, Reduction, Refinement).
Detailed description
The development of radioligands targeting structures of diagnostic or therapeutic interest is a central challenge in nuclear medicine. However, their selection still relies primarily on animal models, which are poorly representative of human tissue, limiting clinical transposability and delaying innovation, in contradiction with the ethical principles of animal experimentation. Recent work has highlighted the value of ex vivo approaches on human tissue to better anticipate the specificity of radioligand binding, while reducing the need for animal models. Autohistoradiography, in particular, allows precise visualization of the tissue distribution of radiolabeled molecules, without systemic interference. The HERO project aims to structure an ex vivo screening platform, based on anonymized human tissues, to early assess the tissue fixation of experimental ligands in an ethical, translational approach that complies with the principles of the 3Rs (Replacement, Reduction, Refinement).
Interventions
OTHEREarly assessment of tissue uptake of experimental ligands
Ex vivo evaluation of the binding of experimental radiolabeled ligands on human tissue using autohistoradiography
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Patients who underwent surgical resection at the Nancy University Hospital after 2019 (Information provided in the welcome booklet or on posters displayed in waiting rooms, mentioning the possible use of data or resection specimens, unless otherwise stated). * No documented objection, in accordance with the MR004 methodology. * Frozen human tissues (slides, blocks, or sections) from surgical resection or biopsy, transmitted by the CRB or the biopathology department. * Samples are fully anonymized before being made available for analysis.
Exclusion criteria
* • Unusable tissue (degraded, insufficient, contaminated, poorly preserved). * Lack of traceability of the material. * Explicit opposition from the patient to the use of their tissue for research.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ex vivo evaluation of the binding of experimental radiolabeled ligands on human tissue by autohistoradiography | 10 days | Signal /background noise ration, in region of interest |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Identify specific tissue fixation profiles according to the nature of the molecules (Antibodies, peptides, nanobodies, etc.). | 1 day | Signal/background noise ratio (calculated between the target area and a healthy area on the same slice). |
| Compare the biodistribution of the molecule of interest between different types of tissues (tumor, inflammatory, healthy, etc.). | 10 days | Analysis of biodistribution across the entire section (depending on the nature of the tissue). |
| Identify ligands exhibiting specific and relevant tissue binding, warranting further in vivo evaluation. | 1 year | Inter-tissue differences (tumor, inflammatory, healthy tissue, etc.) for the same molecule. |
Countries
France
Contacts
CONTACTCaroline BOURSIER, MD
CONTACTVéronique ROCH, MSc
Outcome results
None listed